Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Posted January 10, 2023
Seller of CBD Warned for COVID-19 Claims
On January 5, 2023, the FDA issued a warning to PharmaCanna after review of the company’s website and social media, which found statements about the company’s cannabidiol (CBD) product, CBDefense 2000, to be drug claims because they promoted the products to prevent or treat COVID-19.
For example, PharmaCanna’s CBD was promoted with statements such as, “COVID prevention with CBD? Canada study shows it's possible. Might be time to start a daily dose of PharmaCanna's all-natural pharmaceutical grade CBD products…. USE CODE: COV19.” And, “If you are dealing with patients looking for covid vaccines, covid tests, and anything related to anti-covid, then PharmaCanna may have the revolutionary product for your patients. We introduce CBDefense 2000 with 1000mg of CBD/CBDA and 1000mg of CBG/CBGA. . . . “
PharmaCanna is required respond to the agency within 15 days of receipt of the letter outlining any steps to address any violations.
For more information and tests of related products, see ConsumerLab’s CBD & Hemp Extract Supplements, Lotions, and Balms Review.
Also see Do any supplements help with coronavirus (COVID-19)? Do supplements like vitamin D, zinc, vitamin C, or herbals work?
For more information, use the link below.
Warning: PharmaCanna
See related recalls and warnings:
CBD Not Permitted in Gummies, Candies, Cookies, Candy, or Pet Treats, Says FDA
Seller of CBD Warned for COVID-19 Claims
CBD Products Were Promoted to Treat Cancer and Alzheimer’s Without Proof, Says FTC
Maker of Care by Design CBD Settles Charges of Unsupported Claims
CBD Seller Warned for Drug and COVID-19 Claims